Stocktwits on MSN

Moderna Stock Slides After-Hours On CMV Vaccine Failure In Phase 3 Trial — Retail Traders Warn Of ‘Endless’ Cash Burn

Moderna said its cytomegalovirus (CMV) vaccine, mRNA-1647, failed to prevent infection in women of childbearing age in a ...

Moderna Stops CMV Program As Vaccine Falls Short In Preventing Infection

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...
BioSpace

Moderna Scraps CMV Vaccine After Phase III Fail

A key question for investors going forward will be whether Moderna's other latent virus vaccines for Epstein-Barr and ...
BioPharma Dive

Moderna says CMV vaccine once seen as future blockbuster fails key study

A shot analysts projected as a multibillion-dollar seller produced results “well below” the company’s expectations, ...
Clinical Trials Arena on MSN

Moderna scraps mRNA vaccine in congenital CMV on Phase III failure

While development has been scrapped in CMV, a Phase II trial investigating the candidate in bone marrow transplant patients ...
PharmExec

Moderna Ceases Development of mRNA-1647 After Failing to Reach Primary Goal in Clinical Trial

Moderna announced its decision to cease development of its vaccine mRNA-1647, which was being designed to treat birth defects ...

Moderna says key study of its CMV vaccine, expected to be its next big win, failed

It's a significant setback for the Cambridge company, which is already facing pressure from Wall Street and the federal government.

Moderna Announces Phase 3 Study of Investigational Cytomegalovirus (CMV) Vaccine Did Not Meet Primary Efficacy Endpoint

Company to discontinue development of mRNA-1647 in congenital CMV Company will continue to evaluate mRNA-1647 in ongoing Phase 2 trial in bone marrow transplant patients Company does not anticipate ...